Fig. 4

Univariate and multivariate COX regression to study survival after guadecitabine. a In univariate COX regression analyses, significant factors in univariate analyses were PB blasts (HR = 1.01, 95% CI 1.01–1.02, p < 0.0001), z4-score (HR = 0.85, 95% CI 0.78–0.91, p < 0.0001), BM blasts (HR = 1.02, 95% CI 1.01–1.02, p = 0.0002), RAS mutation (HR = 2.53, 95% CI 1.45–3.92, p = 0.0004), cytogenetic risk (HR = 2.18, 95% CI 1.41–3.17, p = 0.0004), cluster R (HR = 2.03, 95% CI 1.26–3.17, p = 0.003), hemoglobin value (HR = 0.86, 95% CI 0.75–0.99, p = 0.03), IDH2 mutation (HR = 0.47, 95% CI 0.23–0.98, p = 0.044), and mutated gene number (HR = 1.20, 95% CI 1.00–1.43, p = 0.048). b In a multivariate analysis by backward regression, cytogenetic risk (HR = 2.25, 95% CI 1.46–3.48, p = 0.0003), z4-score (HR = 0.89, 95% CI 0.81–0.97, p = 0.01), the presence of RAS mutation (HR = 2.12, 95% CI 1.19–3.76, p = 0.01), and hemoglobin value (HR = 0.86, 95% CI 0.74–0.99, p = 0.04) were significant predictors of survival